Physician

Simil S. Gala, M.D.

According to 2025 Medicare claims, Simil Gala, M.D. (NPI: 1073716445) practices cardiology in the Green Bay, WI market, with the plurality of this provider's patient population coming from Brown, WI. This provider's primary affiliated billing organization is ST VINCENT HOSPITAL-HOSPITAL SISTERS-THIRD ORDER OF ST FRANCIS (NPI: 1285613638; TIN: 39-0817529) and primary practice location at 54301-3526. Gala is affiliated with the HSHS ACO, L.L.C. (ACO ID: A2783), participating under the MSSP model.

Gala's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,367 traditional Medicare patients, billed 4,432 HCPCS/CPT codes, and received $213,752 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 16,466 prescription claims across 2,212 beneficiaries totaling $2,876,164 in drug costs, led by Eliquis (Apixaban). 2019 DME data shows 13 claims. Open Payments data shows 39 records totaling $181,921. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $256,593 to $2,876,164. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	910	3,583	$197,098
2016	1,032	4,099	$218,259
2017	1,047	4,867	$241,658
2018	1,078	5,161	$235,780
2019	1,195	5,467	$285,917
2020	1,190	4,912	$227,541
2021	1,660	5,441	$265,089
2022	1,411	4,518	$217,519
2023	1,311	4,086	$195,754
2024	1,367	4,432	$213,752

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	653	5,813	$256,593
2016	763	6,827	$368,810
2017	921	7,616	$523,938
2018	1,021	8,488	$651,989
2019	1,178	9,081	$796,217
2020	1,323	10,144	$1,180,031
2021	1,610	11,933	$1,516,622
2022	1,789	13,452	$1,972,869
2023	1,934	14,019	$2,556,078
2024	2,212	16,466	$2,876,164

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	13	$26,142
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	401	424	$84
78452	Nuclear medicine studies of heart muscle at rest and with stress and spect	204	208	$55
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	600	620	$49
93018	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician	208	212	$10
99152	Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes	189	207	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	1,242	79,014	$1,506,428
Xarelto	Rivaroxaban	247	18,160	$333,804
Repatha Sureclick	Evolocumab	358	14,324	$281,550
Entresto	Sacubitril/Valsartan	186	10,055	$219,370
Brilinta	Ticagrelor	104	5,658	$80,460

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	38	$938	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$180,983	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Simil S. Gala, M.D.?

Tedicare shows public-source Medicare data for Simil S. Gala, M.D. (NPI 1073716445), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Simil S. Gala, M.D. have ACO affiliation data?

Simil S. Gala, M.D. is shown with ACO affiliation data for HSHS ACO, L.L.C. (MSSP, ACO ID A2783).

What billing organization is linked to Simil S. Gala, M.D.?

Simil S. Gala, M.D. is linked to ST VINCENT HOSPITAL-HOSPITAL SISTERS-THIRD ORDER OF ST FRANCIS (billing NPI 1285613638) in the available physician profile data.

Does Simil S. Gala, M.D. have Open Payments data?

Simil S. Gala, M.D. has 39 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.